東誠藥業(ye)(002675)6月21日晚間公(gong)(gong)告，公(gong)(gong)司控股(gu)子公(gong)(gong)司煙臺藍(lan)(lan)納(na)成(cheng)(cheng)生物技術有限公(gong)(gong)司擬以(yi)增資(zi)(zi)(zi)擴股(gu)方式，引入東誠藥業(ye)、景(jing)林景(jing)盈(ying)、新動能(neng)基(ji)金、動能(neng)嘉元(yuan)、業(ye)達投(tou)(tou)資(zi)(zi)(zi)、伯信投(tou)(tou)資(zi)(zi)(zi)、藍(lan)(lan)色藥谷、源(yuan)禾春熙、牟新投(tou)(tou)資(zi)(zi)(zi)9位投(tou)(tou)資(zi)(zi)(zi)者，合(he)計出資(zi)(zi)(zi)2億元(yuan)按照20.46元(yuan)/份出資(zi)(zi)(zi)額的對價(jia)，認購藍(lan)(lan)納(na)成(cheng)(cheng)新增注冊資(zi)(zi)(zi)本(ben)。此次(ci)增資(zi)(zi)(zi)擴股(gu)完成(cheng)(cheng)后，公(gong)(gong)司持有藍(lan)(lan)納(na)成(cheng)(cheng)54.87%的股(gu)份。藍(lan)(lan)納(na)成(cheng)(cheng)此次(ci)增資(zi)(zi)(zi)擴股(gu)有利于(yu)優化股(gu)權結(jie)構，充盈(ying)資(zi)(zi)(zi)金儲備，加快(kuai)研發產品進展，爭取產品早日上市。